All Sections
action:article | category:AGGREGATION | adString:AGGREGATION | zoneID:2
Welcome guest, you have 3 views left. | Register | Sign In

NH Angle is a news and information aggregation by staff and audience of the New Hampshire Union Leader, The Goffstown News, The Bedford Bulletin, The Hooksett Banner and The Salem Observer. Share a news link here or comment on this item below.

Manch-based Boston Therapeutics closes $5.3M placement of common stock, warrants

Proceeds of the offering will be used to fund additional clinical trials for PAZ320, a non-systemic chewable drug designed to reduce the elevation of postprandial glucose or post-meal blood sugar for treatment of patients with Type 2 diabetes, and for general corporate purposes.

CLICK TO VIEW THE SOURCE MATERIAL


Post a comment


You must sign in before you can post comments. If you are experiencing issues with your account please e-mail abuse@unionleader.com.


Most Popular

action:article | category:AGGREGATION | adString:AGGREGATION | zoneID:88